
Asia Pacific Academy of Science Pte. Ltd. (APACSCI) specializes in international journal publishing. APACSCI adopts the open access publishing model and provides an important communication bridge for academic groups whose interest fields include engineering, technology, medicine, computer, mathematics, agriculture and forestry, and environment.

Effect of the APP17 peptide on diabetic encephalopathy
Vol 33, Issue 1, 2019
Abstract
This study aimed to investigate the effect of the APP17 peptide on diabetic encephalopathy. Streptozotocin (STZ)-induced type 2 diabetes mellitus rats were used to obtain a model of diabetic encephalopathy with cognitive impairment. After treatment with APP17 peptide, the changes in blood glucose levels, body weight, and memory ability in the model rats were observed. Glucose metabolism was detected by Positron Emission Tomography/Computerized Tomography (PET/CT) in brain of rats from each group. After 12 weeks of STZ-induced diabetes, the escape latency of the diabetic encephalopathy (DE) group was significantly prolonged compared with the normal control (NC) group (p<0.05) and the uptake of glucose in the cerebral cortex and hippocampus was decreased compared with the NC group. The glucose uptake was significantly increased in the group treated with APP17 (APP17+DE), compared with the DE groups and the level of glucose metabolism in brain tissue was greatly improved (p<0.05). In conclusion, it was confirmed that APP17 peptide could improve the cognitive function and glucose metabolism in diabetic encephalopathy rats.
Keywords
References
Supporting Agencies
Copyright (c) 2019 LJ. Liu, XJ. Lu, JM. Gao, RJ. Wang, GX. Cheng
This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Medical Genetics, University of Torino Medical School, Italy

Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy